Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
The aim of T-cell-based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2012-12, Vol.18 (24), p.6580-6587 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6587 |
|---|---|
| container_issue | 24 |
| container_start_page | 6580 |
| container_title | Clinical cancer research |
| container_volume | 18 |
| creator | CHEN, Daniel S IRVING, Bryan A STEPHEN HODI, F |
| description | The aim of T-cell-based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing signs that programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) inhibitors are highly active. Preclinical and early data from clinical studies suggest that targeting this pathway can induce durable clinical responses in patients in a variety of tumor types, including lung and colon cancer. Furthermore, correlations with tumor PD-L1 expression may enable selection of patients most likely to benefit from treatment. The emerging data not only offer the hope of better cancer therapy but also provide evidence that changes our understanding of how the host immune system interacts with human cancer. |
| doi_str_mv | 10.1158/1078-0432.ccr-12-1362 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1551641483</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1240901161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-22167cb4c8146ebea5650cb8d0a6005f1df1327d030bd50c1e0dbc06f0bf08e73</originalsourceid><addsrcrecordid>eNqFkctO3DAUhi1Exa19BFA2SGw8Pce3pOyqocBI03aE6NpyHGcmVS6DnYjOjpfoC_IkOJoBFl1042PrfP_x0f8TcoowQZTZZ4Q0oyA4m1jrKTKKXLE9coRSppQzJffj_ZU5JMch_AZAgSAOyCHjkKUCsiOy_t7Vzg618cnC9KtHswmXyQ_3p6c3rnXe9FXXJrOmGdquX8X3evP89DeZtasqr_qqXSYL3y29aRpXJFcuTqDzamnaIsFkPP_p4kfyoTR1cJ929YT8uv52P72l8583s-nXObVSsJ4yhiq1ubAZCuVyZ6SSYPOsAKMAZIlFiZylBXDIi9hBB0VuQZWQl5C5lJ-Qi-3cte8eBhd63VTBuro2reuGoKNPqASKjP8fZQK-AKLCiMotan0XgnelXvuqMX6jEfSYix4916Pnejq9i1I95hJ1Z7svhjya8aZ6DSIC5zvABGvq0pvWVuGdU6lUcQv-AnEDlto</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1240901161</pqid></control><display><type>article</type><title>Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>CHEN, Daniel S ; IRVING, Bryan A ; STEPHEN HODI, F</creator><creatorcontrib>CHEN, Daniel S ; IRVING, Bryan A ; STEPHEN HODI, F</creatorcontrib><description>The aim of T-cell-based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing signs that programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) inhibitors are highly active. Preclinical and early data from clinical studies suggest that targeting this pathway can induce durable clinical responses in patients in a variety of tumor types, including lung and colon cancer. Furthermore, correlations with tumor PD-L1 expression may enable selection of patients most likely to benefit from treatment. The emerging data not only offer the hope of better cancer therapy but also provide evidence that changes our understanding of how the host immune system interacts with human cancer.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.ccr-12-1362</identifier><identifier>PMID: 23087408</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Animals ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; B7-H1 Antigen - antagonists & inhibitors ; B7-H1 Antigen - metabolism ; Biological and medical sciences ; Biomarkers, Tumor - antagonists & inhibitors ; Biomarkers, Tumor - metabolism ; Humans ; Immunologic Factors - pharmacology ; Immunologic Factors - therapeutic use ; Immunotherapy ; Medical sciences ; Molecular Targeted Therapy ; Neoplasms - immunology ; Neoplasms - therapy ; Pharmacology. Drug treatments ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - metabolism</subject><ispartof>Clinical cancer research, 2012-12, Vol.18 (24), p.6580-6587</ispartof><rights>2014 INIST-CNRS</rights><rights>2012 AACR.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-22167cb4c8146ebea5650cb8d0a6005f1df1327d030bd50c1e0dbc06f0bf08e73</citedby><cites>FETCH-LOGICAL-c542t-22167cb4c8146ebea5650cb8d0a6005f1df1327d030bd50c1e0dbc06f0bf08e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3356,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26756409$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23087408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHEN, Daniel S</creatorcontrib><creatorcontrib>IRVING, Bryan A</creatorcontrib><creatorcontrib>STEPHEN HODI, F</creatorcontrib><title>Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>The aim of T-cell-based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing signs that programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) inhibitors are highly active. Preclinical and early data from clinical studies suggest that targeting this pathway can induce durable clinical responses in patients in a variety of tumor types, including lung and colon cancer. Furthermore, correlations with tumor PD-L1 expression may enable selection of patients most likely to benefit from treatment. The emerging data not only offer the hope of better cancer therapy but also provide evidence that changes our understanding of how the host immune system interacts with human cancer.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>B7-H1 Antigen - antagonists & inhibitors</subject><subject>B7-H1 Antigen - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - antagonists & inhibitors</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Humans</subject><subject>Immunologic Factors - pharmacology</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunotherapy</subject><subject>Medical sciences</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Programmed Cell Death 1 Receptor - metabolism</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctO3DAUhi1Exa19BFA2SGw8Pce3pOyqocBI03aE6NpyHGcmVS6DnYjOjpfoC_IkOJoBFl1042PrfP_x0f8TcoowQZTZZ4Q0oyA4m1jrKTKKXLE9coRSppQzJffj_ZU5JMch_AZAgSAOyCHjkKUCsiOy_t7Vzg618cnC9KtHswmXyQ_3p6c3rnXe9FXXJrOmGdquX8X3evP89DeZtasqr_qqXSYL3y29aRpXJFcuTqDzamnaIsFkPP_p4kfyoTR1cJ929YT8uv52P72l8583s-nXObVSsJ4yhiq1ubAZCuVyZ6SSYPOsAKMAZIlFiZylBXDIi9hBB0VuQZWQl5C5lJ-Qi-3cte8eBhd63VTBuro2reuGoKNPqASKjP8fZQK-AKLCiMotan0XgnelXvuqMX6jEfSYix4916Pnejq9i1I95hJ1Z7svhjya8aZ6DSIC5zvABGvq0pvWVuGdU6lUcQv-AnEDlto</recordid><startdate>20121215</startdate><enddate>20121215</enddate><creator>CHEN, Daniel S</creator><creator>IRVING, Bryan A</creator><creator>STEPHEN HODI, F</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20121215</creationdate><title>Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1</title><author>CHEN, Daniel S ; IRVING, Bryan A ; STEPHEN HODI, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-22167cb4c8146ebea5650cb8d0a6005f1df1327d030bd50c1e0dbc06f0bf08e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>B7-H1 Antigen - antagonists & inhibitors</topic><topic>B7-H1 Antigen - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - antagonists & inhibitors</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Humans</topic><topic>Immunologic Factors - pharmacology</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunotherapy</topic><topic>Medical sciences</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Programmed Cell Death 1 Receptor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHEN, Daniel S</creatorcontrib><creatorcontrib>IRVING, Bryan A</creatorcontrib><creatorcontrib>STEPHEN HODI, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHEN, Daniel S</au><au>IRVING, Bryan A</au><au>STEPHEN HODI, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2012-12-15</date><risdate>2012</risdate><volume>18</volume><issue>24</issue><spage>6580</spage><epage>6587</epage><pages>6580-6587</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><abstract>The aim of T-cell-based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing signs that programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) inhibitors are highly active. Preclinical and early data from clinical studies suggest that targeting this pathway can induce durable clinical responses in patients in a variety of tumor types, including lung and colon cancer. Furthermore, correlations with tumor PD-L1 expression may enable selection of patients most likely to benefit from treatment. The emerging data not only offer the hope of better cancer therapy but also provide evidence that changes our understanding of how the host immune system interacts with human cancer.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>23087408</pmid><doi>10.1158/1078-0432.ccr-12-1362</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2012-12, Vol.18 (24), p.6580-6587 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1551641483 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Animals Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - metabolism Biological and medical sciences Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - metabolism Humans Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Immunotherapy Medical sciences Molecular Targeted Therapy Neoplasms - immunology Neoplasms - therapy Pharmacology. Drug treatments Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - metabolism |
| title | Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20Pathways:%20Next-Generation%20Immunotherapy%E2%80%95%20Inhibiting%20Programmed%20Death-Ligand%201%20and%20Programmed%20Death-1&rft.jtitle=Clinical%20cancer%20research&rft.au=CHEN,%20Daniel%20S&rft.date=2012-12-15&rft.volume=18&rft.issue=24&rft.spage=6580&rft.epage=6587&rft.pages=6580-6587&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/10.1158/1078-0432.ccr-12-1362&rft_dat=%3Cproquest_cross%3E1240901161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1240901161&rft_id=info:pmid/23087408&rfr_iscdi=true |